Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021

Rhea-AI Summary

Recro Pharma (NASDAQ: REPH) will release its Q2 2021 financial results on August 9, 2021, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss these results and recent operational highlights. Recro operates as a contract development and manufacturing organization (CDMO), specializing in complex formulation and manufacturing challenges for oral solid dose drugs. The company boasts extensive capabilities, from early feasibility to commercial manufacturing, within a 120,000 square feet facility located in Gainesville, Georgia.

Positive

• Scheduled release of Q2 2021 financial results indicates transparency and engagement with investors.
• Possesses a significant 120,000 square feet facility that enhances operational capacity.

Negative

• None.

Conference Call and Webcast Scheduled for Monday, August 9, 2021 at 4:30 p.m. Eastern

EXTON, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that the company will release financial results for the second quarter 2021 after the market close on Monday, August 9, 2021. Recro’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, August 9, 2021 to discuss the financial results and recent operational highlights.

To access the live conference call please dial (844) 243-4691 from the U.S. or (225) 283-0379 from outside the U.S. at least ten minutes prior to the start time and reference conference ID 1658678. Those interested in listening to the conference call live via webcast may do so by visiting the “Events” page in the Investor section of the Company’s website, www.recrocdmo.com. In addition, an archived webcast will be available on the Company’s website approximately two hours after the event and will be available for 30 days.

About Recro
Recro (NASDAQ: REPH) is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.

In addition to our experience in handling DEA controlled substances and developing and manufacturing modified release oral solid dosage forms, Recro has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 120,000 square feet, in Gainesville, Georgia.

For more information about Recro’s CDMO solutions, visit recrocdmo.com.

FAQ

When will Recro Pharma announce its Q2 2021 financial results?

Recro Pharma will announce its Q2 2021 financial results on August 9, 2021, after market close.

What time is the conference call for Recro Pharma's financial results?

The conference call for Recro Pharma's financial results is scheduled for 4:30 p.m. ET on August 9, 2021.

How can I listen to Recro Pharma's conference call?

You can listen to Recro Pharma's conference call by dialing (844) 243-4691 from the U.S. or (225) 283-0379 from outside the U.S. Alternatively, you can access the live webcast on Recro's Investor section of their website.

What services does Recro Pharma provide?

Recro Pharma provides contract development and manufacturing services for oral solid dosage forms, including regulatory support, clinical and commercial manufacturing, and logistics services.